Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
申请人:——
公开号:US20030186989A1
公开(公告)日:2003-10-02
Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of Formula (1.0.0):
1
wherein R
5
and R
6
are taken together to form a moiety of partial Formulas (1.1.1) through (1.1.5):
2
or a pharmaceutically acceptable salt thereof.
METHOD FOR PRODUCING METAL PARTICLE DISPERSION, CONDUCTIVE INK USING METAL PARTICLE DISPERSION PRODUCED BY SUCH METHOD, AND CONDUCTIVE COATING FILM
申请人:Toyo Ink Mfg. Co., Ltd
公开号:EP1952918A1
公开(公告)日:2008-08-06
Disclosed is a method for producing a metal particle dispersion wherein a metal compound is reduced by using carbodihydrazide represented by the formula (1) below or a polybasic acid polyhydrazide represented by the formula (2) below (wherein R represents an n-valent polybasic acid residue) in a liquid medium. By reducing the metal compound in the presence of a compound having a function preventing discoloration of the metal, there can be obtained a metal particle dispersion having excellent discoloration preventing properties. Metal particles produced by such methods have a uniform particle diameter and are excellent in dispersion stability. By using a conductive resin composition or conductive ink containing a metal particle dispersion obtained by such production methods, there can be formed a conductive coating film, such as a conductive circuit or an electromagnetic layer, having good characteristics.
本发明公开了一种生产金属颗粒分散液的方法,该方法通过在液体介质中使用下式 (1) 所代表的碳二酰肼或下式 (2) 所代表的多基酸多酰肼(其中 R 代表正价多基酸残基)还原金属化合物。通过在具有防止金属褪色功能的化合物存在下还原金属化合物,可获得具有优异防褪色性能的金属颗粒分散液。通过这种方法制得的金属颗粒具有均匀的颗粒直径和出色的分散稳定性。使用含有通过这种生产方法获得的金属颗粒分散体的导电树脂组合物或导电墨水,可以形成具有良好特性的导电涂膜,例如导电电路或电磁层。
Hemoglobin modifier compounds and uses thereof
申请人:FronThera U.S. Pharmaceuticals LLC
公开号:US10787430B2
公开(公告)日:2020-09-29
Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagnose blood-based diseases, disorders or conditions.